Nkarta (NKTX) Announces $150M Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on tech boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil prices rise on Trump timeline for Iran peace deal: after US elections
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Nkarta (NKTX) Surges 55% After Announcing Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
April 25, 2022 7:12 AM EDTNkarta (NASDAQ: NKTX) Surges 55% After Announcing Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
... MoreNkarta (NKTX) Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
April 25, 2022 7:03 AM EDTNkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive preliminary Phase 1 data from independent dose finding studies of its two lead chimeric antigen receptor (CAR) natural killer (NK) cell therapy candidates, NKX101 and NKX019, in two distinct groups of hematologic malignancies.
Were excited to see our CAR NK co-lead candidates, NKX101 and NKX019, show such striking early single-agent activity in heavily pretreated patient populations, with an exceptional safety profile without the side effects associated with CAR T cell therapies, said Paul J.... More
